Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study-Reference-Cited by-同舟云学术

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

Published:2017-12 Issue:12 Volume:4 Page:e595-e606
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Snijder Berend,Vladimer Gregory I,Krall Nikolaus,Miura Katsuhiro,Schmolke Ann-Sofie,Kornauth Christoph,Lopez de la Fuente Oscar,Choi Hye-Soo,van der Kouwe Emiel,Gültekin Sinan,Kazianka Lukas,Bigenzahn Johannes W,Hoermann Gregor,Prutsch Nicole,Merkel Olaf,Ringler Anna,Sabler Monika,Jeryczynski Georg,Mayerhoefer Marius E,Simonitsch-Klupp Ingrid,Ocko Katharina,Felberbauer Franz,Müllauer Leonhard,Prager Gerald W,Korkmaz Belgin,Kenner Lukas,Sperr Wolfgang R,Kralovics Robert,Gisslinger Heinz,Valent Peter,Kubicek Stefan,Jäger Ulrich,Staber Philipp B,Superti-Furga Giulio

Publisher

Elsevier BV

Subject

Hematology

Reference39 articles.

1. Acute myeloid leukaemia;Khwaja;Nat Rev Dis Primers,2016

2. Predictive, personalized, preventive, participatory (P4) cancer medicine;Hood;Nat Rev Clin Oncol,2011

3. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses;Tsimberidou;Clin Cancer Res,2014

4. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers;Von Hoff;J Clin Oncol,2010

5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial;Le Tourneau;Lancet Oncol,2015

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies;JCO Precision Oncology;2024-01

2. PI3Kδ Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and Enhancing Gene Regulation;Cancers;2023-12-27

3. A New Microfluidic Device to Facilitate Functional Precision Medicine Assays;Methods in Molecular Biology;2023-12-10

4. Standardized assays to monitor drug sensitivity in hematologic cancers;Cell Death Discovery;2023-12-01

5. Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell Carcinoma;2023-10-19